- Report
- May 2024
- 125 Pages
Global
From €5428EUR$5,950USD£4,668GBP
- Report
- February 2025
- 200 Pages
Global
From €4096EUR$4,490USD£3,523GBP
- Report
- March 2025
- 150 Pages
Global
From €4425EUR$4,850USD£3,805GBP
- Report
- August 2024
- 143 Pages
Global
From €2736EUR$2,999USD£2,353GBP
- Report
- March 2025
- 180 Pages
Global
From €4105EUR$4,500USD£3,531GBP
- Report
- March 2025
- 130 Pages
Global
From €3982EUR$4,365USD£3,425GBP
€4425EUR$4,850USD£3,805GBP
- Report
- February 2024
- 120 Pages
Global
From €4333EUR$4,750USD£3,727GBP
- Report
- June 2022
- 215 Pages
United States
From €2462EUR$2,699USD£2,118GBP
- Report
- January 2020
United States
From €1268EUR$1,390USD£1,091GBP
- Report
- December 2018
- 14 Pages
Global
From €9123EUR$10,000USD£7,846GBP
- Report
- January 2025
- 85 Pages
Global
From €3500EUR$4,110USD£3,115GBP
Pneumovax is a vaccine used to protect against pneumococcal disease, a type of bacterial infection that can cause pneumonia, meningitis, and other serious illnesses. It is recommended for adults over the age of 65, as well as those with certain medical conditions. The vaccine is administered as a single dose, and is available in both injectable and intranasal forms.
The pneumococcal vaccine market is a growing segment of the overall vaccine market, with increasing demand for the vaccine due to its effectiveness in preventing serious illnesses. The market is expected to continue to grow in the coming years, driven by rising awareness of the importance of vaccination and increasing government initiatives to promote immunization.
The pneumococcal vaccine market is highly competitive, with several major players. These include Merck & Co., GlaxoSmithKline, Pfizer, Sanofi, and AstraZeneca. Show Less Read more
